| scholarly article | Q13442814 |
| P50 | author | Michael J Dapp | Q57555080 |
| Lauren Beach | Q59784284 | ||
| P2093 | author name string | Louis M Mansky | |
| Richard H Heineman | |||
| Jonathan M Rawson | |||
| Steven E Patterson | |||
| Jessica L Martin | |||
| Erica K Schnettler | |||
| P2860 | cites work | RNA virus error catastrophe: direct molecular test by using ribavirin | Q24599371 |
| Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity | Q27470003 | ||
| Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus | Q27480816 | ||
| Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine | Q28331877 | ||
| A phase I clinical, plasma, and cellular pharmacology study of gemcitabine | Q28334915 | ||
| Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication | Q28368051 | ||
| Lethal mutagenesis of HIV with mutagenic nucleoside analogs | Q28369649 | ||
| Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin | Q28370147 | ||
| Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections | Q28471847 | ||
| Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461 | Q28476736 | ||
| A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine | Q29616154 | ||
| Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase | Q29619994 | ||
| Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious | Q31047702 | ||
| Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate | Q33784748 | ||
| Exploiting drug repositioning for discovery of a novel HIV combination therapy | Q34124794 | ||
| 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. | Q35000909 | ||
| Viral error catastrophe by mutagenic nucleosides | Q35919839 | ||
| Lethal mutagenesis of HIV. | Q36008905 | ||
| Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase | Q36145017 | ||
| Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects | Q36554938 | ||
| Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. | Q37700645 | ||
| Clinical trials of resveratrol | Q37831946 | ||
| Resveratrol and health--a comprehensive review of human clinical trials | Q37891928 | ||
| Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine | Q39471085 | ||
| Back to the future: revisiting HIV-1 lethal mutagenesis | Q39511261 | ||
| 5-Azacytidine Hydrolysis Kinetics Measured by High-Pressure Liquid Chromatography and 13C-NMR Spectroscopy | Q39554910 | ||
| Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides | Q40110178 | ||
| Mutation Frequencies at Defined Single Codon Sites in Vesicular Stomatitis Virus and Poliovirus Can Be Increased Only Slightly by Chemical Mutagenesis | Q40110327 | ||
| Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection | Q40412986 | ||
| KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis | Q40423448 | ||
| Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). | Q40653667 | ||
| Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis | Q40714016 | ||
| Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses | Q41104028 | ||
| Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation | Q41640905 | ||
| Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides | Q42282585 | ||
| Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication | Q42282677 | ||
| Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine | Q42400705 | ||
| Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol | Q43511988 | ||
| The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen | Q43545743 | ||
| Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases | Q43812620 | ||
| Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method | Q46980232 | ||
| Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. | Q54122138 | ||
| Action of 2',2'-difluorodeoxycytidine on DNA synthesis | Q67702699 | ||
| Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine | Q68408993 | ||
| Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis | Q68917155 | ||
| 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase | Q70215052 | ||
| Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators | Q72639469 | ||
| High-performance Liquid Chromatographic Analysis of Chemical Stability of 5-aza-2′-Deoxycytidine | Q72650148 | ||
| Resveratrol, a remarkable inhibitor of ribonucleotide reductase | Q74191674 | ||
| Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults | Q84142908 | ||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7222-7228 | |
| P577 | publication date | 2013-08-20 | |
| P1433 | published in | Bioorganic & Medicinal Chemistry | Q2904200 |
| P1476 | title | 5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors | |
| P478 | volume | 21 |
| Q39514817 | 5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2'-Deoxycytidine. |
| Q37547746 | Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1 |
| Q38705926 | Disparate Contributions of Human Retrovirus Capsid Subdomains to Gag-Gag Oligomerization, Virus Morphology, and Particle Biogenesis |
| Q36725172 | Dual anti-HIV mechanism of clofarabine |
| Q35834559 | HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation |
| Q26749548 | New strategies against drug resistance to herpes simplex virus |
| Q38967949 | Novel inhibitors of human immunodeficiency virus type 2 infectivity |
| Q38808216 | Rapid Determination of HIV-1 Mutant Frequencies and Mutation Spectra Using an mCherry/EGFP Dual-Reporter Viral Vector |
| Q38610855 | Resveratrol, sirtuins, and viruses |
| Q34303615 | Retroviral vectors for analysis of viral mutagenesis and recombination |
| Q36371387 | Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra. |
| Q59356354 | The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations |
Search more.